MedTrace Logo

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

NCT05170828 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-02-24

No results posted yet for this study

Summary

Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.

Conditions

Interventions

DRUG

Cyclophosphamide

pre-transplant conditioning treatment

DRUG

Fludarabine

pre-transplant conditioning treatment

RADIATION

Total Body Irradiation

pre-transplant conditioning treatment

DRUG

Busulfan

pre-transplant conditioning treatment

DRUG

Mesna

given with cyclophosphamide

DRUG

Sirolimus

post-transplant treatment for GVHD

DRUG

Mycophenolate Mofetil

post-transplant treatment for GVHD

DRUG

Filgrastim

post-transplant treatment for GVHD

DRUG

Cyclophosphamide

post-transplant treatment for GVHD

PROCEDURE

Bone Marrow Transplant

Transplant with investigational bone marrow product

Sponsors & Collaborators

  • Ossium Health, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2024-03-31
Completion
2024-11-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05170828 on ClinicalTrials.gov